Fee Schedule & Payer Contract Intelligence

Structural Revenue — No Additional Volume Required

Fee schedule optimization is the only revenue improvement that requires zero additional patients, zero additional chair time, and zero additional team capacity. If a practice's fee schedule is systematically below market on high-volume codes, every procedure performed generates less revenue than it should — and that structural gap compounds with every patient visit, every day, every month.

This is not about raising prices aggressively. It is about ensuring that the practice's fee schedule reflects the market reality for its geography and procedure mix. A practice in a metropolitan market charging suburban rates on its ten highest-volume CDT codes is leaving structural revenue on the table — not because of clinical performance or patient volume, but because the fee schedule hasn't been benchmarked against current market data.

For founders evaluating an exit, fee schedule optimization has a unique characteristic: it flows directly to EBITDA with no additional expense. A $50 increase on a code performed 1,500 times annually adds $75,000 to revenue with zero incremental cost. At a 6x multiple, that's $450,000 in enterprise value created by adjusting numbers in a spreadsheet. No other operational improvement has a comparable effort-to-value ratio.

The CDT Code-Level Approach

While most practices guess at annual fee increases — or simply apply a blanket 3-5% across the board — institutional buyers use national payer databases to check if your D4341 (scaling and root planing) or D2751 (porcelain/ceramic crown) is sitting below the 75th percentile for your specific zip code.

This is the forensic approach PDA brings to fee schedule analysis: not a blanket percentage increase, but a code-by-code, production-weighted analysis that identifies exactly where the revenue gap is largest.

A practice may be appropriately priced on 80% of its codes but materially underpriced on the 5-10 high-volume codes that drive 40%+ of production. The blanket increase misses this entirely — it raises already-competitive codes unnecessarily while underestimating the adjustment needed on the codes that actually matter.

The Production-Weighted Methodology

PDA doesn't just identify which codes are below market. It calculates the annualized revenue impact by multiplying the per-code gap by annual procedure volume. Underpricing a code you perform 2,000 times per year costs far more than underpricing a code you perform 50 times. The analysis isolates the exact codes where the gap has the highest annualized revenue impact — without requiring a single additional patient.

Example: A practice performing D2751 (porcelain crown) 400 times annually at an office fee of $1,150 when the 75th percentile for their zip code is $1,340 has a per-procedure gap of $190. Annualized: $76,000 in structural revenue left on the table on a single code. At a 6x multiple, that's $456,000 in enterprise value — from one line item on the fee schedule.

The 75th percentile is the strategic target because it positions the practice competitively without creating insurance friction. Fees at the 90th percentile or above may trigger UCR-based reductions from insurance carriers, reducing the effective benefit. The 75th percentile maximizes revenue capture while maintaining insurance payment levels.

Payer Contract Anomalies

Independent payer-level analysis sometimes reveals systematic collection differentials that have no clinical explanation — identical procedures, dramatically different collection outcomes by carrier.

One carrier collecting at 51% against an 85% practice-wide baseline is a 34-point anomaly that aggregate reporting masks entirely. These anomalies typically have one of three root causes:

Fee Schedule Misalignment

The practice's contracted rate with that carrier is significantly below the practice's UCR fee schedule or below the carrier's own table of allowances. This happens when PPO contracts are signed and never revisited — the carrier's rates remain static while the practice's costs and market rates increase. After 3-5 years, the gap becomes material.

Systematic Claims Processing Denials

The carrier systematically denies specific procedure codes due to documentation requirements, bundling rules, frequency limitations, or pre-authorization requirements that the practice isn't meeting. These denials suppress the collection rate for that carrier specifically and often go undetected because the denied claims are written off rather than appealed.

Alternate Benefit Calculations

Some carriers apply "alternate benefit" rules that reimburse for a less expensive procedure when they deem the performed procedure is not the most cost-effective treatment. A porcelain crown billed at $1,200 might be reimbursed at the amalgam filling rate of $180 under an alternate benefit clause. These reductions appear as write-offs and are rarely appealed.

Each root cause has a different remediation path. The first step in every case is identifying which carriers have anomalous collection rates — something that practice-wide aggregate reporting will never reveal.

Phantom PPO Write-offs

Revenue that exists on the daily production sheet but gets structurally written off at the collection tier due to uncapped fee schedules on PPO contracts. This is one of the most common sources of phantom revenue in PPO-heavy practices.

The mechanic: the practice "produces" at its UCR fee schedule — recording, say, $1,400 for a crown. But the PPO contracted rate is $950. The $450 difference is treated as a contractual write-off. On the daily production report, the practice sees $1,400. On the collections report, it sees $950. The write-off is structural, predictable, and baked into every single procedure on every single PPO patient.

Under QoE, this differential creates a specific problem: it inflates top-line production figures while depressing the collection rate. A practice showing $2M in production but $1.4M in collections has a 30% gap. Some of that gap is legitimate (patient deductibles, claim delays). But if the majority is PPO contractual write-offs, the buyer's QoE team will normalize the production figure down to the collectible amount and evaluate EBITDA on collections-adjusted revenue.

The PPO Dependency Trap

Practices that are heavily PPO-dependent (60%+ of production) often show strong production numbers with mediocre collection rates. The production looks healthy; the margin doesn't. This creates a narrative problem in the transaction: the buyer sees high volume but low yield, which signals either a fee schedule problem or a coding/billing problem. Both suppress the multiple.

The QoE Implication

Underpriced fee schedules are not just a revenue miss — they represent a growth asset that sophisticated buyers recognize. A practice with fee schedule optimization headroom has identifiable, low-risk revenue upside that doesn't require operational changes. For the buyer, it's "free" revenue that can be captured post-closing simply by adjusting the fee schedule to market rates.

However: if the fee schedule is so far below market that production figures appear inflated relative to collections, QoE analysts will flag the collection rate as a revenue quality concern. The buyer can't tell whether the low collection rate is caused by fee schedule misalignment (benign, fixable) or by coding problems and claim denials (serious, systemic). The burden of proof falls on the seller to demonstrate which it is.

This is why optimized practices pre-sanitize their own ledgers. They audit their payer mix quarterly. They negotiate or drop toxic PPOs proactively. They benchmark their fee schedule against current market data annually — not with a blanket percentage increase, but with a code-level analysis weighted by procedure volume. Every vulnerability that surfaces as a surprise in QoE costs more than the same vulnerability identified and remediated 18 months before the transaction.